Literature DB >> 27449494

Advances in Targeted Drug Delivery Approaches for the Central Nervous System Tumors: The Inspiration of Nanobiotechnology.

Jianing Meng1, Vivek Agrahari2, Ibrahima Youm3.   

Abstract

At present, brain tumor is among the most challenging diseases to treat and the therapy is limited by the lack of effective methods to deliver anticancer agents across the blood-brain barrier (BBB). BBB is a selective barrier that separates the circulating blood from the brain extracellular fluid. In its neuroprotective function, BBB prevents the entry of toxins, as well as most of anticancer agents and is the main impediment for brain targeted drug delivery approaches. Nanotechnology-based delivery systems provide an attractive strategy to cross the BBB and reach the central nervous system (CNS). The incorporation of anticancer agents in various nanovehicles facilitates their delivery across the BBB. Moreover, a more powerful tool in brain tumor therapy has relied surface modifications of nanovehicles with specific ligands that can promote their passage through the BBB and favor the accumulation of the drug in CNS tumors. This review describes the physiological and anatomical features of the brain tumor and the BBB, and summarizes the recent advanced approaches to deliver anticancer drugs into brain tumor using nanobiotechnology-based drug carrier systems. The role of specific ligands in the design of functionalized nanovehicles for targeted delivery to brain tumor is reviewed. The current trends and future approaches in the CNS delivery of therapeutic molecules to tumors are also discussed.

Entities:  

Keywords:  Blood-brain barrier; Blood-brain tumor barrier; Brain tumor; CNS; Drug delivery; Drug transport; Ligand targeting; Nanocarrier; Nanoformulation

Mesh:

Substances:

Year:  2016        PMID: 27449494     DOI: 10.1007/s11481-016-9698-1

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN: 1557-1890            Impact factor:   4.147


  165 in total

1.  Electrical resistance across the blood-brain barrier in anaesthetized rats: a developmental study.

Authors:  A M Butt; H C Jones; N J Abbott
Journal:  J Physiol       Date:  1990-10       Impact factor: 5.182

2.  American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012.

Authors:  Quinn T Ostrom; Haley Gittleman; Peter M de Blank; Jonathan L Finlay; James G Gurney; Roberta McKean-Cowdin; Duncan S Stearns; Johannes E Wolff; Max Liu; Yingli Wolinsky; Carol Kruchko; Jill S Barnholtz-Sloan
Journal:  Neuro Oncol       Date:  2016-01       Impact factor: 12.300

3.  Cyclic RGD-linked polymeric micelles for targeted delivery of platinum anticancer drugs to glioblastoma through the blood-brain tumor barrier.

Authors:  Yutaka Miura; Tomoya Takenaka; Kazuko Toh; Shourong Wu; Hiroshi Nishihara; Mitsunobu R Kano; Yasushi Ino; Takahiro Nomoto; Yu Matsumoto; Hiroyuki Koyama; Horacio Cabral; Nobuhiro Nishiyama; Kazunori Kataoka
Journal:  ACS Nano       Date:  2013-09-18       Impact factor: 15.881

4.  Dual Receptor-Targeted Theranostic Nanoparticles for Localized Delivery and Activation of Photodynamic Therapy Drug in Glioblastomas.

Authors:  Suraj Dixit; Kayla Miller; Yun Zhu; Emilie McKinnon; Thomas Novak; Malcolm E Kenney; Ann-Marie Broome
Journal:  Mol Pharm       Date:  2015-08-24       Impact factor: 4.939

5.  Lactoferrin-conjugated biodegradable polymersome holding doxorubicin and tetrandrine for chemotherapy of glioma rats.

Authors:  Zhiqing Pang; Liang Feng; Rongrong Hua; Jun Chen; Huile Gao; Shuaiqi Pan; Xinguo Jiang; Peng Zhang
Journal:  Mol Pharm       Date:  2010-10-28       Impact factor: 4.939

6.  Glucose transporter and folic acid receptor-mediated Pluronic P105 polymeric micelles loaded with doxorubicin for brain tumor treating.

Authors:  Jiangxiu Niu; Aidong Wang; Zhongcheng Ke; Zubiao Zheng
Journal:  J Drug Target       Date:  2014-05-07       Impact factor: 5.121

Review 7.  Magnetic nanoparticles for tumor imaging and therapy: a so-called theranostic system.

Authors:  Huining He; Allan David; Beata Chertok; Adam Cole; Kyuri Lee; Jian Zhang; Jianxin Wang; Yongzhuo Huang; Victor C Yang
Journal:  Pharm Res       Date:  2013-01-24       Impact factor: 4.200

Review 8.  Novel delivery approaches for cancer therapeutics.

Authors:  Ashim K Mitra; Vibhuti Agrahari; Abhirup Mandal; Kishore Cholkar; Chandramouli Natarajan; Sujay Shah; Mary Joseph; Hoang M Trinh; Ravi Vaishya; Xiaoyan Yang; Yi Hao; Varun Khurana; Dhananjay Pal
Journal:  J Control Release       Date:  2015-10-09       Impact factor: 9.776

Review 9.  Nanoparticle therapeutics: an emerging treatment modality for cancer.

Authors:  Mark E Davis; Zhuo Georgia Chen; Dong M Shin
Journal:  Nat Rev Drug Discov       Date:  2008-09       Impact factor: 84.694

10.  The application of magnetic nanoparticles for the treatment of brain tumors.

Authors:  Keon Mahmoudi; Costas G Hadjipanayis
Journal:  Front Chem       Date:  2014-12-03       Impact factor: 5.221

View more
  8 in total

1.  Nanomedicines for the Treatment of CNS Diseases.

Authors:  Jessica L Reynolds; Ram I Mahato
Journal:  J Neuroimmune Pharmacol       Date:  2017-02-01       Impact factor: 4.147

Review 2.  Covalent nano delivery systems for selective imaging and treatment of brain tumors.

Authors:  Julia Y Ljubimova; Tao Sun; Leila Mashouf; Alexander V Ljubimov; Liron L Israel; Vladimir A Ljubimov; Vida Falahatian; Eggehard Holler
Journal:  Adv Drug Deliv Rev       Date:  2017-06-10       Impact factor: 15.470

Review 3.  The exciting potential of nanotherapy in brain-tumor targeted drug delivery approaches.

Authors:  Vivek Agrahari
Journal:  Neural Regen Res       Date:  2017-02       Impact factor: 5.135

Review 4.  Surface Modification of Iron Oxide-Based Magnetic Nanoparticles for Cerebral Theranostics: Application and Prospection.

Authors:  Yanyue Wu; Zhiguo Lu; Yan Li; Jun Yang; Xin Zhang
Journal:  Nanomaterials (Basel)       Date:  2020-07-24       Impact factor: 5.076

Review 5.  Nasal Drug Delivery of Anticancer Drugs for the Treatment of Glioblastoma: Preclinical and Clinical Trials.

Authors:  Franciele Aline Bruinsmann; Gustavo Richter Vaz; Aline de Cristo Soares Alves; Tanira Aguirre; Adriana Raffin Pohlmann; Silvia Stanisçuaski Guterres; Fabio Sonvico
Journal:  Molecules       Date:  2019-11-26       Impact factor: 4.411

Review 6.  Nanocarriers Call the Last Shot in the Treatment of Brain Cancers.

Authors:  Amin Mehrabian; Mohammad Mashreghi; Saba Dadpour; Ali Badiee; Leila Arabi; Seyedeh Hoda Alavizadeh; Seyedeh Alia Moosavian; Mahmoud Reza Jaafari
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec

Review 7.  Lysosomal Storage Disease-Associated Neuropathy: Targeting Stable Nucleic Acid Lipid Particle (SNALP)-Formulated siRNAs to the Brain as a Therapeutic Approach.

Authors:  Maria Francisca Coutinho; Juliana Inês Santos; Liliana S Mendonça; Liliana Matos; Maria João Prata; Amália S Jurado; Maria C Pedroso de Lima; Sandra Alves
Journal:  Int J Mol Sci       Date:  2020-08-10       Impact factor: 5.923

Review 8.  Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment.

Authors:  Joshua R D Pearson; Stefania Cuzzubbo; Simon McArthur; Lindy G Durrant; Jason Adhikaree; Chris J Tinsley; A Graham Pockley; Stephanie E B McArdle
Journal:  Front Immunol       Date:  2020-10-15       Impact factor: 7.561

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.